Suoyuan Biology and Kaijie Company Reach Cooperation to Help the Development of Tumor Precision Therapy


Release time:

2021-12-10

On December 10, Soyuan Bio and Kaijie Corporation (QIAGEN) jointly announced that the two companies will cooperate in the development of blood-based companion diagnostic (CDx) products on a global scale.

On December 10, Soyuan Biology and QIAGEN Company (QIAGEN) jointly announced that they will cooperate in the development of blood-based companion diagnostic (CDx) products worldwide for the detection of DGM1(Denovo Genomic Marker 1), a newly discovered drug genome biomarker of Soyuan Biology, to predict patients with diffuse large B lymphoma (DLBCL) who have curative effect on DB102(enzastaurin). DB102 is a PKC beta inhibitor currently undergoing international multicenter phase 3 clinical trials.

DB102 is a small molecule serine/threonine kinase inhibitor with "first-in-class" potential acquired by Soyuan Bio from Eli Lilly and Company, which acts on key tumor targets in tumor fields such as PKCβ, PI3K and AKT. The drug candidate has a direct effect of inducing tumor cell death and blocking tumor cell proliferation, as well as an indirect effect of inhibiting tumor-induced angiogenesis. After the acquisition of DB102, Soyuan Bio used its biomarker discovery platform to discover a new set of biomarkers DGM1, DGM1-positive patients have a very significant improvement in survival after taking DB102.